FMP

FMP

Enter

OVID - Ovid Therapeutics Inc.

Profile of Ovid Therapeutics Inc.(OVID), Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and f

About

ceo

Dr. Jeremy Max Levin Ba Zoology, Dphil, Mb Bchir

sector

Healthcare

industry

Biotechnology

website

https://www.ovidrx.com

exchange

NASDAQ

Description

Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815 for the treatment of kinesin-family of proteins associated neurological disorder. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

CIK

0001636651

ISIN

US6904691010

CUSIP

690469101

Address

1460 Broadway

Phone

646 661 7661

Country

US

Employee

40

IPO Date

May 5, 2017

Key Executives

page loading card
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep